Literature DB >> 15711814

[Drug therapy of female urinary incontinence].

C Hampel1, R Gillitzer, S Pahernik, S W Melchior, J W Thüroff.   

Abstract

Drug treatment for female urinary incontinence requires a thorough knowledge of the differential diagnosis and pathophysiology of incontinence as well as of the pharmacological agents employed. Pharmacotherapy has to be tailored to suit the incontinence subtype and should be carefully balanced according to efficacy and side effects of the drug. Women with urge incontinence require treatment that relaxes or desensitizes the bladder (antimuscarinics, estrogens, alpha-blockers, beta-mimetics, botulinum toxin A, resiniferatoxin, vinpocetine), whereas patients with stress incontinence need stimulation and strengthening of the pelvic floor and external sphincter (alpha-mimetics, estrogens, duloxetine). Females with overflow incontinence need reduction of outflow resistance (baclofen, alpha-blockers, intrasphincteric botulinum toxin A) and/or improvement of bladder contractility (parasympathomimetics). If nocturia or nocturnal incontinence are the major complaints, control of diuresis is obtained by administration of the ADH analogue desmopressin. Future developments will help to further optimize the pharmacological therapy for female urinary incontinence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711814     DOI: 10.1007/s00120-005-0769-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  23 in total

1.  Treatment of neurogenic incontinence with botulinum toxin A.

Authors:  B Schurch; D M Schmid; M Stöhrer
Journal:  N Engl J Med       Date:  2000-03-02       Impact factor: 91.245

Review 2.  Therapeutic opportunities from muscarinic receptor research.

Authors:  R M Eglen; A Choppin; N Watson
Journal:  Trends Pharmacol Sci       Date:  2001-08       Impact factor: 14.819

Review 3.  [Changes in the receptor profile of the aging bladder].

Authors:  C Hampel; R Gillitzer; S Pahernik; S W Melchior; J W Thüroff
Journal:  Urologe A       Date:  2004-05       Impact factor: 0.639

4.  Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier.

Authors:  C Pakulski; L Drobnik; B Millo
Journal:  Med Sci Monit       Date:  2000 Mar-Apr

5.  Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride.

Authors:  A Grüneberger
Journal:  Br J Obstet Gynaecol       Date:  1984-03

6.  Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.

Authors:  B Schurch; M Stöhrer; G Kramer; D M Schmid; G Gaul; D Hauri
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

Review 7.  Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder.

Authors:  M B Chancellor; W C de Groat
Journal:  J Urol       Date:  1999-07       Impact factor: 7.450

8.  M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.

Authors:  Ken Ikeda; Seiji Kobayashi; Mami Suzuki; Keiji Miyata; Makoto Takeuchi; Toshimitsu Yamada; Kazuo Honda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-06-14       Impact factor: 3.000

9.  The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input.

Authors:  Carlos Silva; Maria Jose Ribeiro; Francisco Cruz
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

10.  Serotonergic facilitation of facial motoneuron excitation.

Authors:  R B McCall; G K Aghajanian
Journal:  Brain Res       Date:  1979-06-15       Impact factor: 3.252

View more
  6 in total

Review 1.  [Urinary incontinence and urodynamics].

Authors:  K-P Jünemann; H Palmtag; C Hampel; H Heidler; G Naumann; H Kölbl; C van der Horst; D Schultz-Lampel
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  [Intravesical therapy for overactive bladder].

Authors:  J Pannek; U Grigoleit; R Wormland; M Goepel
Journal:  Urologe A       Date:  2006-02       Impact factor: 0.639

3.  [Intraprostatic botulinum toxin A injection in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS)].

Authors:  T Bschleipfer; F M E Wagenlehner; W Weidner
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

Review 4.  [Treatment of overactive bladder in elderly and old people].

Authors:  M Zellner
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639

5.  Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study.

Authors:  Chung-Jing Wang; Shi-Wei Huang; Chien-Hsing Chang
Journal:  Urol Res       Date:  2009-03-10

6.  Subcutaneous tunneling of the temporary testing electrode significantly improves the success rate of subchronic sacral nerve modulation (SNM).

Authors:  Karl-Dietrich Sievert; Udo Nagele; Juergen Pannek; Daniel Engeler; Markus Kuczyk; Arnulf Stenzl
Journal:  World J Urol       Date:  2007-10-03       Impact factor: 4.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.